SEO URLwww.firestrike.ai/deals/cidara-therapeutics-merck-acquisition-2026-2
acquisitionAnnounced · Feb 9, 2026BiotechnologySource · CredibleArticle · Factual
Merck acquires Cidara Therapeutics
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$9.2B
Target
Cidara Therapeutics
NASDAQ:CDTX
Acquirer
Merck
Full Acquisition
Status
Pending
Merck agreed to acquire Cidara Therapeutics. Reported deal value: $9.2B. Status: Pending. Sector: Biotechnology. Target headquarters context: Location not specified.
This page summarizes publicly available information about the transaction as of 2026-02-09. Figures and status may change as filings and press coverage update.
Published Category Biotech Latest News Merck has completed its cash tender offer to acquire Cidara Therapeutics , marking a further addition to its respiratory disease portfolio
Deal timeline
Announced
Feb 9, 2026 · thehealthcaretechnologyreport.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Biotechnology with a reported deal value of $9.2B. Figures and status may change as sources update.
Sources: thehealthcaretechnologyreport.com · Primary article · FireStrike proprietary index